Search Results - "Weigel, Brenda J"

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study by Mossé, Yael P, Dr, Lim, Megan S, MD, Voss, Stephan D, MD, Wilner, Keith, PhD, Ruffner, Katherine, MD, Laliberte, Julie, Rolland, Delphine, Balis, Frank M, Prof, Maris, John M, Prof, Weigel, Brenda J, MD, Ingle, Ashish M, MS, Ahern, Charlotte, PhD, Adamson, Peter C, Prof, Blaney, Susan M, Prof

“…Summary Background Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma,…”
Get full text

Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group by Kopp, Lisa M., Malempati, Suman, Krailo, Mark, Gao, Yun, Buxton, Allen, Weigel, Brenda J., Hawthorne, Thomas, Crowley, Elizabeth, Moscow, Jeffrey A., Reid, Joel M., Villalobos, Victor, Randall, R. Lor, Gorlick, Richard, Janeway, Katherine A.

“…The prognosis is poor for children and adolescents with recurrent osteosarcoma (OS). Glycoprotein non-metastatic B (gpNMB) is a glycoprotein highly expressed…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report by BENDER, Julia L. Glade, LEE, Alice, WEIGEL, Brenda J, BLANEY, Susan M, REID, Joel M, BARUCHEL, Sylvain, ROBERTS, Timothy, VOSS, Stephan D, BING WU, AHERN, Charlotte H, INGLE, Ashish M, HARRIS, Pamela

“…Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic…”
Get full text

A Phase 1 Study of ABI‐009 (Nab‐sirolimus) in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors—A Children's Oncology Group Pediatric Early Phase Clinical Trial Network Study ADVL1514 by Cramer, Stuart L., Reddy, Alyssa Terry, Minard, Charles Gene, Voss, Stephan, Fox, Elizabeth, Liu, Xiaowei, Denic, Kristina, Reid, Joel M., Weigel, Brenda J.

“…ABSTRACT Background Nab‐sirolimus (ABI‐009, nab‐rapamycin; Aadi Bioscience Inc. [Aadi]) is a human albumin‐bound form of sirolimus nanoparticles, a potent mTOR…”
Get full text

Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model by Dicovitsky, Rose H, Schappa, Jill T, Schulte, Ashley J, Lang, Haeree P, Kuerbitz, Ellen, Roberts, Sarah, DePauw, Taylor A, Lewellen, Mitzi, Winter, Amber L, Stuebner, Kathy, Buettner, Michelle, Reid, Kelly, Bergsrud, Kelly, Pracht, Sara, Chehadeh, Andrea, Feiock, Caitlin, O'Sullivan, M Gerard, Carlson, Tim, Armstrong, Alexandra R, Meritet, Danielle, Henson, Michael S, Weigel, Brenda J, Modiano, Jaime F, Borgatti, Antonella, Vallera, Daniel A

“…EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only…”
Get full text

Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial by Davis, Kara L, Fox, Elizabeth, Merchant, Melinda S, Reid, Joel M, Kudgus, Rachel A, Liu, Xiaowei, Minard, Charles G, Voss, Stephan, Berg, Stacey L, Weigel, Brenda J, Mackall, Crystal L

“…Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in adults with cancer, but data on these drugs in children are scarce. We did a phase…”
Get full text

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors by Mascarenhas, Leo, Ogawa, Chitose, Laetsch, Theodore W., Weigel, Brenda J., Bishop, Michael W., Krystal, Julie, Borinstein, Scott C., Slotkin, Emily K., Muscal, Jodi A., Hingorani, Pooja, Levy, Donna E., Mo, Gary, Shahir, Ashwin, Wright, Jennifer, DuBois, Steven G.

“…Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We…”
Get full text

CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma by WEIGEL, Brenda J, RODEBERG, David A, KRIEG, Arthur M, BLAZAR, Bruce R

“…Purpose: CpG oligodeoxynucleotides (ODNs) are synthetic DNA sequences that mimic bacterial DNA and have potent immunostimulatory effects on dendritic cells…”
Get full text

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study by Mossé, Yael P, Voss, Stephan D, Lim, Megan S, Rolland, Delphine, Minard, Charles G, Fox, Elizabeth, Adamson, Peter, Wilner, Keith, Blaney, Susan M, Weigel, Brenda J

“…Purpose Fusions involving the ALK gene are the predominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory…”
Get full text

A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study by WEIGEL, Brenda J, BLANEY, Susan M, GILBERTSON, Richard J, KRAILO, Mark, AMES, Matthew, ADAMSON, Peter C, REID, Joel M, SAFGREN, Stephanie L, BAGATELL, Rochelle, KERSEY, John, NEGLIA, Joseph P, IVY, S. Percy, INGLE, Ashish M, WHITESELL, Luke

“…Purpose: To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein…”
Get full text

Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials by London, Wendy B., Bagatell, Rochelle, Weigel, Brenda J., Fox, Elizabeth, Guo, Dongjing, Van Ryn, Collin, Naranjo, Arlene, Park, Julie R.

“…BACKGROUND Early‐phase trials in patients with recurrent neuroblastoma historically used an objective “response” of measureable disease (Response Evaluation…”
Get full text

3488 A comparison between the Rolling 6 and 3+3 dose escalation study designs for phase 1 clinical trials by Minard, Charles Gene, Rau, Rachel, Hilsenbeck, Susan, Weigel, Brenda J., Fox, Elizabeth, Adamson, Peter, Blaney, Susan

“…OBJECTIVES/SPECIFIC AIMS: The development of new anti-cancer agents for children requires an inherently longer timeline than in adults. The 3+3 study design…”
Get full text

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) by Foster, Jennifer H, Voss, Stephan D, Hall, David C, Minard, Charles G, Balis, Frank M, Wilner, Keith, Berg, Stacey L, Fox, Elizabeth, Adamson, Peter C, Blaney, Susan M, Weigel, Brenda J, Mossé, Yael P

“…Anaplastic lymphoma kinase (ALK) aberrations are a promising target for patients with neuroblastoma. We assessed the activity of first-generation ALK inhibitor…”
Get full text

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia by Zhou, Qing, Munger, Meghan E., Veenstra, Rachelle G., Weigel, Brenda J., Hirashima, Mitsuomi, Munn, David H., Murphy, William J., Azuma, Miyuki, Anderson, Ana C., Kuchroo, Vijay K., Blazar, Bruce R.

“…Tumor-associated immune suppression can lead to defective T cell-mediated antitumor immunity. Here, we identified a unique phenotype of exhausted T cells in…”
Get full text

Children's Oncology Group's 2023 blueprint for research: Developmental therapeutics by Fox, Elizabeth, Parsons, D. Williams, Weigel, Brenda J.

“…The Developmental Therapeutics Committee (DVL) identifies and develops new agents and treatment strategies for children/adolescents with cancer, through…”
Get full text

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group by Weigel, Brenda J, Lyden, Elizabeth, Anderson, James R, Meyer, William H, Parham, David M, Rodeberg, David A, Michalski, Jeff M, Hawkins, Douglas S, Arndt, Carola A S

“…Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free survival (EFS)…”
Get full text

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial by Cole, Peter D, McCarten, Kathleen M, Pei, Qinglin, Spira, Menachem, Metzger, Monika L, Drachtman, Richard A, Horton, Terzah M, Bush, Rizvan, Blaney, Susan M, Weigel, Brenda J, Kelly, Kara M

“…Patients with primary refractory Hodgkin's lymphoma or early relapse have a poor prognosis. Although many salvage regimens have been developed, there is no…”
Get full text

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) by Mossé, Yael P, Fox, Elizabeth, Teachey, David T, Reid, Joel M, Safgren, Stephanie L, Carol, Hernan, Lock, Richard B, Houghton, Peter J, Smith, Malcolm A, Hall, David, Barkauskas, Donald A, Krailo, Mark, Voss, Stephan D, Berg, Stacey L, Blaney, Susan M, Weigel, Brenda J

“…Aurora A kinase (AAK) plays an integral role in mitotic entry, DNA damage checkpoint recovery, and centrosome and spindle maturation. Alisertib (MLN8237) is a…”
Get full text

Racial and Ethnic Differences in Sarcoma Incidence Are Independent of Census-Tract Socioeconomic Status by Diessner, Brandon J, Weigel, Brenda J, Murugan, Paari, Zhang, Lin, Poynter, Jenny N, Spector, Logan G

“…Epidemiologic analyses of sarcoma are limited by the heterogeneity and rarity of the disease. Utilizing population-based surveillance data enabled us to…”
Get full text

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group by Malempati, Suman, Weigel, Brenda J, Chi, Yueh-Yun, Tian, Jing, Anderson, James R, Parham, David M, Teot, Lisa A, Rodeberg, David A, Yock, Torunn I, Shulkin, Barry L, Spunt, Sheri L, Meyer, William H, Hawkins, Douglas S

“…The outcome for patients with metastatic rhabdomyosarcoma (RMS) remains poor. A previous Children's Oncology Group (COG) study (ARST0431) for patients with…”
Get full text